Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hoth Therapeutics Inc (HOTH)
NASDAQ:HOTH
Holding HOTH?
Track your performance easily
HOTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.58 - $1.73
Previous Close$0.79
Volume8.62M
Average Volume (3M)978.31K
Market Cap
$5.43M
Enterprise Value$5.47M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$33.81K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Nov 10, 2020EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding6,903,804
10 Day Avg. Volume86,116
30 Day Avg. Volume978,306
Standard Deviation0.25
R-Squared0.03
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.44
Forecast
1Y Price Target
$3.50Price Target Upside360.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Hoth Therapeutics News
Bulls Say, Bears Say
Bulls Say
Alzheimer's Disease TherapeuticsHoth Therapeutics announced the grant of a U.S. patent for its pioneering Alzheimer's disease therapeutic candidate, designated HT-ALZ.
Artificial Intelligence In Drug DevelopmentHoth entered into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of NVIDIA Corporation.
Financial PerformanceHoth Therapeutics reported a net loss of $0.24 per share, which was narrower than the forecast for a net loss of $0.39 per share.
Bears Say
Financial RiskNear- to medium-term equity dilution risk could negatively impact shareholder value.
Product DevelopmentFailure to advance HT-001 development in a timely manner poses a significant risk.
Regulatory ApprovalThere is a risk of inability to achieve regulatory approval of HT-001.
---
Ownership Overview
1.01% Insiders
1.48% Mutual Funds
0.47% Other Institutional Investors
96.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
HOTH FAQ
What was Hoth Therapeutics Inc’s price range in the past 12 months?
Hoth Therapeutics Inc lowest stock price was $0.58 and its highest was $1.73 in the past 12 months.
What is Hoth Therapeutics Inc’s market cap?
Currently, no data Available
When is Hoth Therapeutics Inc’s upcoming earnings report date?
Hoth Therapeutics Inc’s upcoming earnings report date is Nov 10, 2020 which is 1509 days ago.
How were Hoth Therapeutics Inc’s earnings last quarter?
Hoth Therapeutics Inc released its earnings results on Aug 13, 2020. The company reported -$5 earnings per share for the quarter, missing the consensus estimate of N/A by -$5.
Is Hoth Therapeutics Inc overvalued?
According to Wall Street analysts Hoth Therapeutics Inc’s price is currently Undervalued.
Does Hoth Therapeutics Inc pay dividends?
Hoth Therapeutics Inc does not currently pay dividends.
What is Hoth Therapeutics Inc’s EPS estimate?
Hoth Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hoth Therapeutics Inc have?
Hoth Therapeutics Inc has 6,903,804 shares outstanding.
What happened to Hoth Therapeutics Inc’s price movement after its last earnings report?
Hoth Therapeutics Inc reported an EPS of -$5 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Hoth Therapeutics Inc?
Currently, no hedge funds are holding shares in HOTH
---
Company Description
Hoth Therapeutics Inc
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.
---
HOTH Stock 12 Month Forecast
Average Price Target
$3.50
▲(360.53% Upside)
Technical Analysis
Best Analysts Covering HOTH
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-12.98%
reiterated a buy rating 2 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -12.98% per trade.
---